How Smart4Diagnostics Spent EIC Accelerator Money on Blood Samples

Between the needle and the laboratory analyser, a blood sample spends hours in a tube that nobody watches. It can sit in a warm car, be shaken in transit, be drawn into the wrong tube or underfilled, and the laboratory usually finds out only when the result looks wrong, or not at all. Smart4Diagnostics, a Munich start-up founded in 2018, set out to record that journey for every tube, a "digital data-fingerprint" of each sample from the blood draw to analysis.

The European Commission's list of companies selected at the 9 October 2019 cut-off of the EIC Accelerator pilot names Smart4Diagnostics GmbH of München for the project S4DX, with blended finance, a grant plus EIC equity. The list names no other beneficiary for the project. According to CORDIS, the EU contributed €1,034,075 to a €1,477,250 project that ran from 1 April 2020 to 30 September 2021. Four years after the project ended, the product is on sale in a dozen countries. The company that built it is not: it filed for insolvency in December 2023.

The Company Is Insolvent, the Product Is Not

Smart4Diagnostics filed for insolvency in December 2023. The Munich local court appointed Elske Fehl-Weileder of Schultze & Braun as preliminary insolvency administrator, according to the firm's press release of 18 December 2023, reprinted by Bionity. The release blamed delays in tenders worth "several million euros" whose decisions were not expected until 2024, and said the company could not fund its running costs and software development from operations until then. Wages of the 25 staff were covered by state insolvency pay until the end of February 2024. The commercial register, as shown by North Data, records a court order of 14 December 2023 (case 1542 IN 3587/23) and lists the company in liquidation after a publication on 6 March 2024. The date on which the main proceedings opened is not shown in the free register extracts.

The business survived. Venture Targeter 3 AB, a subsidiary of the Swedish listed investor Katalysen Ventures, bought "all material assets" through a newly founded company, S4DX GmbH, and took over the whole team with effect from 1 March 2024, according to Katalysen's announcement of 14 March 2024 and Munich Startup. Katalysen received a 10.4% stake. The register entry for S4DX GmbH shows a shelf company registered in February 2024 and renamed in March 2024, with Robin Nagel as managing director; the website imprint now names Andreas Kaepplein. A new shareholder list was filed in July 2026.

This article treats Smart4Diagnostics GmbH, the company the EU funded, as insolvent. The technology it built continues under a different legal entity, which is why the outcome is better than the status suggests.

The Technology: A Logbook for Every Tube

Laboratory automation has made analysis inside the lab highly controlled. The weak point is the stage before it. The S4DX final report on CORDIS cites error rates of up to 9.3% in preanalytics and lists the main faults: haemolysis from heat, shock or light, underfilled tubes, the wrong tube type, and mislabelled or lost samples. Beckman Coulter, announcing a partnership with Smart4Diagnostics in May 2022, put the share of preanalytical errors that occur outside the laboratory's control at up to 75% and the average cost of one error at about €200.

Smart4Diagnostics' answer combines hardware and software. At the blood draw, a "sample check-in" registers each tube and gives the phlebotomist handling instructions. In transport, a data logger called SmartTube records time, temperature and shock. On arrival, the data passes into the laboratory information system, so the lab knows the history of each sample before it runs a test. The company website claims "up to 70% preanalytical error reduction"; no independent study confirming that figure was found. The established alternative is paper transport logs, separate temperature loggers in transport boxes and manual checks at the lab entrance, which document a box rather than each tube.

What the EIC Project Promised, and What CORDIS Shows

The CORDIS objective promised a European market entry of a minimum viable product in December 2020, a dataset on the quality of each sample that would become the "data-baseline" for sensitive tests such as liquid biopsy, and pattern-recognition algorithms for personalised diagnostics. It named Roche Diagnostics and Sarstedt as technical advisers and the laboratory chains Bioscientia, Medisupport and Certe as implementation partners.

The final periodic report, covering January to September 2021, is a progress report rather than a results report. It says early adopter testing began with one laboratory in July 2020 and that about 50,000 samples had passed through the system. The market launch with a CE-marked product had slipped from December 2020 to "early 2021"; the report describes the regulatory analysis for the EU medical device and in vitro diagnostics regulations and the technical documentation, but not a completed CE marking. Patent applications were "in the final negotiation phase" with the European Patent Office, and a paper had been submitted to the journal Clinical Chemistry and Laboratory Medicine.

1. Minimum viable product in a live labDeliveredEarly adopter test from July 2020, about 50,000 samples, per the CORDIS report.
2. CE-marked market launch, planned December 2020LateMoved to 2021 in the report; the product was in use in ten countries by May 2023 (EIT) and called CE-approved in October 2025 (Katalysen). The date of the CE marking could not be verified.
3. Patent protectionPartialThree European applications from 2018, including EP3673450A1, are marked withdrawn; a later 2021 publication is listed by North Data, its grant status not verified.
4. Peer-reviewed validation paperNot foundSubmitted to Clinical Chemistry and Laboratory Medicine in 2021; no published paper was found.
5. Pattern recognition and liquid biopsy data baselineNot achievedNo product, study or partner announcement found.

The core of the project, a working tracking system in routine laboratory use, was delivered, though later than planned. The scientific and data ambitions that made the proposal sound like more than logistics software have no public trace.

What Happened After the Grant

The equity side of the blended award arrived with the Series A. In 2021 Smart4Diagnostics closed a round of about €5 million from the tube maker Sarstedt and the EIC Fund, according to the company's lawyers Beiten Burkhardt and Silicon Canals. The register shows the share capital rising from €26,668 to €40,405 in June 2021. How much of the round came from the EIC Fund is not public. Smart4Diagnostics does not appear among the roughly 320 organisations on the EIC Fund's list of invested companies as checked in October 2026, and no source says what happened to the Fund's shares in the insolvency.

Commercial partners followed. Beckman Coulter announced its partnership in May 2022. In May 2023 the company raised a €3.6 million bridge round from VP Venture Partners and Sarstedt, and said its system was used in ten countries, according to EIT. Seven months later it filed for insolvency, working with about 15 laboratories.

Under its new owner, the business has kept growing its footprint. In October 2025 Katalysen said S4DX had shipped 180 SmartTubes to its first UK pilot customer, had won "multiple new UK customers", among them "a major hospital trust", and was deployed in twelve countries, according to its announcement, also published by Börskollen. The same release names Beckman Coulter, Roche and Siemens Healthineers as partners. Katalysen's second-quarter 2026 report lists its S4DX stake at 8%, down from 10.4% at the acquisition, and says the company "continues to gain market traction". The UK hospital trust is not named, and S4DX GmbH's revenue is not public.

Why Europe Should Care

Two EU rulebooks make the problem Smart4Diagnostics works on more pressing. The In Vitro Diagnostic Medical Devices Regulation, which the CORDIS report names as a design requirement, raises documentation demands across diagnostics, and the laboratory standard ISO 15189:2022 now expects traceable control of the preanalytical phase, as Katalysen's 2025 release notes. The European Health Data Space Regulation, in force since 26 March 2025, aims to "establish a common framework for the use and exchange of electronic health data across the EU"; health data are only as useful as the samples behind them. A European supplier of sample-level quality data for laboratories fits that agenda, and the list of large diagnostics partners shows the industry sees the gap.

The Verdict

Smart4Diagnostics, S4DX GmbH and the EIC have not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.